Clinical trials: Dry Eye Symptoms
Dry Eye
Study of EBI-005 in Dry Eye Disease (DED)
This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye…
- Trial name
- EBI-005 (NCT02405039)
- Testing
- EBI-005
- Where
- 12 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eleven Biotherapeutics
Dry Eye Syndrome
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
- Trial name
- NCT01212471
- Testing
- Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms
The purpose of this study is to evaluate the efficacy of Optive versus Systane used concomitantly with topical cyclosporine for the treatment of dry eye.
- Trial name
- NCT00399061
- Testing
- Systane, Optive, Restasis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Innovative Medical
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye
A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye Patients
The purpose of this study is to demonstrate efficacy of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) ophthalmic gel compared to Vehicle for the treatment of dry eye.
- Trial name
- NCT00840268
- Testing
- Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, Hydroxypropyl Guar Galactomannan Vehicle
- Volunteers
- 427 people
- Sponsor
- Alcon Research
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and…
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05825352
- Testing
- Carmellose eye drops
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Dry Eye, Dry Eye Syndromes
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
This study characterizes acute dry eye symptom control, assessed during exposure to a Controlled Adverse Environment, following use of the TrueTear for 45 days.
- Trial name
- NCT03097614
- Testing
- TrueTear
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Oculeve, Inc.
Keratoconjunctivitis Sicca
A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02139033
- Testing
- Retaine™
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Ocusoft, Inc.
Dry Eye
NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye
Study is to assess the safety and efficacy of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions QD compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.
- Trial name
- NCT00739349
- Testing
- NOVA22007 ''Cyclosporine''
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Santen SAS
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline solution) Nasal Spray as compared to placebo (vehicle) on signs and symptoms of dry eye disease.
- Trial name
- NCT05378945
- Testing
- Varenicline Tartrate Nasal Spray
- Where
- 20 sites in China
- Volunteers
- 340 people
- Sponsor
- Corxel Pharmaceuticals
Evaporative Dry Eye
Impact of Tear Substitute Use on Dry Eye in Gamers.
Clinical, prospective, comparative, controlled, single-blind study, on the signs and symptoms of dry eye before and after 3 days of playing video games with the use of artificial tears (Hyabak) versus no intervention.
- Trial name
- HYAGAME (NCT05536661)
- Testing
- Preservative free hyaluronic acid artificial tear
- Where
- Spain
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Laboratorios Thea, Spain
Primary Immune Thrombocytopenia, Sjögren's Syndrome
Managed Access Programs for VAY736, Ianalumab
The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab
- Trial name
- NCT07244289
- Testing
- ianalumab
- Sponsor
- Novartis Pharmaceuticals
Sjögren's Syndrome (SS)
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1.
- Trial name
- NCT06245408
- Testing
- Dazodalibep
- Where
- 194 sites in United States, Argentina and 24 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndrome
Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye
The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT00799552
- Testing
- RX-10045
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Resolvyx Pharmaceuticals, Inc
Dry Eye Disease
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).
- Trial name
- NCT04523129
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 27 sites in United States
- Volunteers
- 834 people
- Sponsor
- Novaliq GmbH
Dry Eye Syndromes
Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control
This study will evaluate the increase in comfort and comfortable contact lens (CL) wear time associated with application of TrueTear (active intranasal neurostimulation) compared with application of TrueTear sham control…
- Trial name
- NCT03325673
- Testing
- TrueTear
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- Allergan
Dry Eye Disease
Systane Complete Multi-symptom Relief
The purpose of this study is to demonstrate effective symptom relief with the use of Systane Complete among subjects with dry eye disease (DED).
- Trial name
- NCT05056155
- Testing
- Systane Complete
- Where
- 4 sites in United States
- Volunteers
- 119 people
- Sponsor
- Alcon Research
Dry Eye
An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication.
- Trial name
- NCT06443775
- Testing
- Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- AbbVie